Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 91

Sort by

Sort Order Select

Journal Articles

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Blood (2024) 143 (6): 496–506.

https://doi.org/10.1182/blood.2023021243

Published: 2024

Includes: Supplemental data

Journal Articles

Deliriogenic Medication Use in Older Adults Receiving CAR-T Correlates with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Michael J. Maranzano, Justin Cheng, John Timmerman, Patricia A. Young, Caspian H. Oliai, Herbert A. Eradat, Sven de Vos, Sarah M. Larson, Monica Mead

Blood (2023) 142 (Supplement 1): 7358.

https://doi.org/10.1182/blood-2023-182105

Published: 2023

Journal Articles

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 602.

https://doi.org/10.1182/blood-2023-179474

Published: 2023

Journal Articles

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

Blood (2023) 142 (Supplement 1): 2095.

https://doi.org/10.1182/blood-2023-189196

Published: 2023

Journal Articles

Updated Follow-up of a Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 3490.

https://doi.org/10.1182/blood-2023-186636

Published: 2023

Journal Articles

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Julio C. Chavez, Michael Dickinson, Javier L. Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha K. Kekre, Sven de Vos, Christine Lui, Jacob Wulff, Chad M. Williams, Weixin Peng, Ioana Kloos, Hairong Xu, Sattva S. Neelapu

Blood (2023) 142 (Supplement 1): 894.

https://doi.org/10.1182/blood-2023-174510

Published: 2023

Journal Articles

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Blood (2023) 142 (Supplement 1): 4868.

https://doi.org/10.1182/blood-2023-174914

Published: 2023

Journal Articles

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Pau Abrisqueta, Raul Cordoba, Lorenzo Falchi, Sven de Vos, Marcel Nijland, Fritz Offner, Jun Wu, Irina Bykhovski, Liwei Wang, Ali Rana, Tycel Phillips

Blood (2022) 140 (Supplement 1): 1068–1069.

https://doi.org/10.1182/blood-2022-158278

Published: 2022

Journal Articles

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

Blood (2022) 140 (Supplement 1): 1464–1466.

https://doi.org/10.1182/blood-2022-158203

Published: 2022

Journal Articles

3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Blood (2022) 140 (Supplement 1): 10380–10383.

https://doi.org/10.1182/blood-2022-156120

Published: 2022

Journal Articles

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Stephen E. Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline C. Barrientos, Sven de Vos, Richard R. Furman, Krish Patel, Philip A. Thompson, Michael Y. Choi, Avyakta Kallam, Sirou Wang, Uzor C. Ogbu, Akash Nahar, Michael L. Wang

Blood (2022) 140 (Supplement 1): 6640–6641.

https://doi.org/10.1182/blood-2022-163509

Published: 2022

Journal Articles

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Sven de Vos, Patrick M. Reagan, Manish R. Patel, Nakhle S. Saba, Andrew Mortlock, Virginie Cerec, Veerendra Munugalavadla, Melih Acar, Barrett Nuttall, David Jenkins, Rafael White, Megan Callahan, Alessandra Forcina, Mark Roschewski, Ian W. Flinn

Blood (2022) 140 (Supplement 1): 6635–6637.

https://doi.org/10.1182/blood-2022-162447

Published: 2022

Journal Articles

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Blood (2021) 138 (Supplement 1): 93.

https://doi.org/10.1182/blood-2021-148473

Published: 2021

Journal Articles

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

Michael Wang, Matthew Mei, Paul M. Barr, Jacqueline Barrientos, Sven de Vos, Richard Furman, Krish Patel, Philip A. Thompson, Michael Choi, Avyakta Kallam, Ying Zhu, Samhita Chakraborty, Patricia Marinello, Stephen E. Spurgeon

Blood (2021) 138 (Supplement 1): 528.

https://doi.org/10.1182/blood-2021-148607

Published: 2021

Journal Articles

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Mark Roschewski, Veerendra Munugalavadla, Barrett Nuttall, Kathleen Burke, Melih Acar, Rafael White, Maria Udriste, Shringi Sharma, Brian Dougherty, Ian Flinn, Nakhle S. Saba, Patrick M. Reagan, Sven de Vos, Hendrik-Tobias Arkenau, Graham P. Collins, Andrew Mortlock, Manish R. Patel

Blood (2021) 138 (Supplement 1): 1418.

https://doi.org/10.1182/blood-2021-147567

Published: 2021

Journal Articles

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Lazaros J. Lekakis, Frederick L. Locke, Michael Tees, Sattva S. Neelapu, Shahbaz A. Malik, Mehdi Hamadani, Matthew J. Frank, Leslie L. Popplewell, Jeremy S. Abramson, Sven de Vos, Javier Munoz, Chu Ri Shin, Arun Balakumaran, Lynn Loomis-Navale, Lovely Goyal, Xiangdong Zhou, David B. Miklos

Blood (2021) 138 (Supplement 1): 649.

https://doi.org/10.1182/blood-2021-146045

Published: 2021

Journal Articles

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Sattva S. Neelapu, Michael Dickinson, Javier Munoz, Matthew L. Ulrickson, Catherine Thieblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Christine Lui, Francesca Milletti, Jinghui Dong, Hairong Xu, Julio C. Chavez

Blood (2021) 138 (Supplement 1): 739.

https://doi.org/10.1182/blood-2021-148009

Published: 2021

Journal Articles

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

Blood (2021) 137 (5): 600–609.

https://doi.org/10.1182/blood.2020006578

Published: 2021

Includes: Supplemental data

Journal Articles

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-136373

Published: 2020

Journal Articles

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Kami J. Maddocks, MD, Johannes Duell, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, Anna Marina Liberati, MD, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MDPhD, Gianluca Gaidano, Pau Abrisqueta, MD PhD, Marc André, MD, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles Salles, MDPhD

Blood (2020) 136 (Supplement 1): 19–21.

https://doi.org/10.1182/blood-2020-140314

Published: 2020

NARROW

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

Deliriogenic Medication Use in Older Adults Receiving CAR-T Correlates with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma

ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas

Updated Follow-up of a Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial

Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update

3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial

Long-Term Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Phase 1 Dose Escalation and Cohort Expansion Study of the Anti-ROR1 Antibody-Drug Conjugate Zilovertamab Vedotin (MK-2140) for the Treatment of Non-Hodgkin Lymphoma

A Phase 1 Study of the Combination of Acalabrutinib and AZD9150 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing

Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Long-Term Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only